Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers-Reference-Cited by-同舟云学术

Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers

Published:2014-11 Issue:11 Volume:9 Page:1669-1674
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Litvak Anya M.,Paik Paul K.,Woo Kaitlin M.,Sima Camelia S.,Hellmann Matthew D.,Arcila Maria E.,Ladanyi Marc,Rudin Charles M.,Kris Mark G.,Riely Gregory J.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non–small-cell lung cancer (EURTAC): a andomized, open-label, andomized phase 3 trial;Rosell;Lancet Oncol,2012

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a andomized, open-label, andomized, phase 3 study;Zhou;Lancet Oncol,2011

5. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J Clin Oncol,2013

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinicopathological significance of mutation profile detected by next generation sequencing in different metastatic organs of non-small cell lung cancers;Pathology - Research and Practice;2024-08

2. Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives;Frontiers in Oncology;2024-07-11

3. Pathways and targeting avenues of BRAF in non-small cell lung cancer;Expert Opinion on Therapeutic Targets;2024-07-02

4. The evolving treatment landscape for BRAF-mutated non-small cell lung cancer;Translational Lung Cancer Research;2024-04

5. Lung adenocarcinoma patients with ROS1-rearranged tumors by sex and smoking intensity;Heliyon;2024-04